Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-GPC3/TCR nanobody SAR444200

A T-cell engaging (TCE) and heavy chain variable domain (VHH)-based nanobody targeting the tumor-associated antigen (TAA) glypican-3 (GPC3; GPC-3) and a T-cell surface antigen, with potential antineoplastic activity. Upon administration, anti-GPC3/TCR nanobody SAR444200 specifically targets and binds to GPC3 expressed on tumor cells and a T-cell surface antigen on cytotoxic T lymphocytes (CTLs). This activates and redirects CTLs to GPC3-expressing tumor cells, leading to CTL-mediated killing of GPC3-expressing tumor cells. GPC3, a heparan sulfate proteoglycan and a member of the glypican family, is overexpressed on certain tumor cell types while minimally expressed in normal, healthy cells. GPC3 plays an important role in tumor cell proliferation in various tumor cell types.
Synonym:SAR-444200
Code name:SAR 444200
SAR444200
Search NCI's Drug Dictionary